Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin flush

Atherosclerosis

Volumn 192, Issue 2, 2007, Pages 253-258

  Meyers, C Daniel ^a   Liu, Paul ^b   Kamanna, Vaijinath S ^a,b   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dyslipidemia; Flush; Niacin; Nicotinic acid; Prostaglandin D2

Indexed keywords

CALCIUM IONOPHORE; NICOTINAMIDE; NICOTINIC ACID; PROSTAGLANDIN D2;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR CALCIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL;

ASPIRIN; CALCIMYCIN; CALCIUM; FLUSHING; HUMANS; MACROPHAGES; MODELS, BIOLOGICAL; NIACIN; NICOTINIC ACIDS; PROSTAGLANDIN D2; TUMOR CELLS, CULTURED;

EID: 34248171687     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.014     Document Type: Article

References (25)

1. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54 (1955) 558-559
2. Meyers C.D., Kamanna V.S., and Kashyap M.L. Niacin therapy in atherosclerosis. Curr Opin Lipidol 15 (2004) 659-665
3. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
4. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
5. Meyers C.D., Carr M.C., Park S., and Brunzell J.D. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 139 (2003) 996-1002
6. Stern R.H., Spence J.D., Freeman D.J., and Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 50 (1991) 66-70
7. Gray D.R., Morgan T., Chretien S.D., and Kashyap M.L. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 121 (1994) 252-258
8. Morrow J.D., Parsons III W.G., and Roberts II L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 (1989) 263-274
9. Morrow J.D., Awad J.A., Oates J.A., and Roberts II L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 98 (1992) 812-815
10. Urade Y., Ujihara M., Horiguchi Y., Ikai K., and Hayaishi O. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol 143 (1989) 2982-2989
11. Boie Y., Sawyer N., Slipetz D.M., Metters K.M., and Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 270 (1995) 18910-18916
12. Cheng K., Wu T.J., Wu K.K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 103 (2006) 6682-6687
13. Schwende H., Fitzke E., Ambs P., and Dieter P. Formation of eicosanoids during differentiation of THP-1 cells. Adv Exp Med Biol 407 (1997) 491-495
14. Faust D., Akoglu B., Faust A.C., and Milovic V. Human peritoneal macrophages in culture: a model for studying inflammatory disorders in vitro. Clin Exp Med 3 (2003) 15-19
15. Stern R.H., Freeman D., and Spence J.D. Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?. Metabolism 41 (1992) 879-881
16. Barrios-Rodiles M., Keller K., Belley A., and Chadee K. Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Biochem Biophys Res Commun 225 (1996) 896-900
17. Jungnickel P.W., Maloley P.A., Vander Tuin E.L., Peddicord T.E., and Campbell J.R. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 12 (1997) 591-596
18. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 (2004) 411-419
19. 2: endogenous PPARgamma ligand or minor eicosanoid degradation product?. J Clin Invest 112 (2003) 828-830
20. Knowles H.J., Te Poole R., Workman P., and Harris A.L. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 71 (2006) 646-656
21. Tang Y., Zhou L., Gunnet J.W., Wines P.G., Cryan E.V., and Demarest K.T. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun (2006)
22. Benyo Z., Gille A., Kero J., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115 (2005) 3634-3640
23. Dupasquier M., Stoitzner P., van Oudenaren A., Romani N., and Leenen P.J. Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse dermis. J Invest Dermatol 123 (2004) 876-879
24. Meunier L., Gonzalez-Ramos A., and Cooper K.D. Heterogeneous populations of class II MHC+ cells in human dermal cell suspensions Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J Immunol 158 (1993) 4067-4080
25. Havel R.J., Carlson L.A., Ekelund L.G., and Holmgren A. Studies on the relation between mobilization of free fatty acids and energy metabolism in man: effects of norepinephrine and nicotinic acid. Metabolism 13 (1964) 1402-1412